X

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
Type of Material
Type of Publication
Consortium
Language
  • 1
    Online Resource
    Online Resource
    Hematopoietic cell transplantation for malignant conditions / (2019)
    St. Louis, Missouri :Elsevier,
    Details
    UID:
    (DE-602)edoccha_9960074094002883
    Format: 1 online resource (439 pages)
    ISBN: 0-323-56803-3
    Note: Front Cover -- Hematopoietic Cell Transplantation for Malignant Conditions -- Hematopoietic Cell Transplantation for Malignant Conditions -- Copyright -- List of Contributors -- Contents -- I - HISTORY AND BASIC SCIENCE OF HEMATOPOIETIC CELL TRANSPLANTATION -- 1 - History and Current Status of Hematopoietic Cell Transplantation -- INTRODUCTION -- BMT Developments in 1950s to Early 1960s -- The Significance of HLA Matching in Transplant -- Late 1960s: The First Successful HLA-Matched Sibling BMTs -- Late 1970s to Mid-1980s: Use of Unrelated Donors -- 1980−90: Use of PB as Autograft -- Early 1990s: Rapid Increase in Allogeneic Transplantation Using PB Grafts -- Haploidentical Stem Cell Transplantation -- History of Umbilical Cord Blood Transplant -- Late 1990s to Early 2000s: Introduction of RIC -- Origin of Donor and Transplant Registries -- CONCLUSION -- REFERENCES -- II - HEMATOPOIETIC CELL TRANSPLANTATION PHARMACOLOGY -- 2 - Pharmacology of Drugs Used in Hematopoietic Cell Transplantation -- INTRODUCTION -- IMMUNOSUPPRESSANTS -- Cyclosporine -- Pearls -- Tacrolimus -- Pearls -- Methotrexate -- Mycophenolate -- Sirolimus -- Pearls -- Cyclophosphamide -- Antithymocyte Globulin -- Pearls -- Alemtuzumab -- Pearls -- Corticosteroids -- Pearls -- ANTIMICROBIAL AGENTS -- Trimethoprim/Sulfamethoxazole -- Piperacillin/Tazobactam -- Pearl -- Cephalosporins -- Carbapenems -- Vancomycin -- Pearl -- Metronidazole -- Antivirals -- Antifungals -- ANTIDIARRHEAL AGENTS -- Loperamide -- Diphenoxylate and Atropine -- Octreotide -- MISCELLANEOUS -- Defibrotide -- Ursodiol -- Deferasirox -- Intravenous Immune Globulin -- Palifermin -- REFERENCES -- 3 - High-Dose Chemotherapy Regimens -- GOALS OF CONDITIONING REGIMENS -- TYPES OF CONDITIONING REGIMENS -- NONCHEMOTHERAPY AGENTS IN CONDITIONING REGIMENS -- Total-Body Irradiation -- Radioisotopes and Radioimmunotherapy. , 90Y-Ibritumomab Tiuxetan -- CHEMOTHERAPY AGENTS IN CONDITIONING REGIMENS -- ALKYLATING AGENTS -- Busulfan -- Cyclophosphamide -- Ifosfamide -- Melphalan -- Thiotepa -- Carmustine -- Bendamustine -- ANTIMETABOLITES -- Fludarabine -- Clofarabine -- Cytarabine -- Gemcitabine -- PLATINUM AGENTS -- Carboplatin -- PLANT ALKALOIDS -- Etoposide -- ANTI-T CELL ANTIBODIES -- MONOCLONAL ANTIBODIES -- Rituximab -- DOSING CONSIDERATIONS -- Organ Dysfunction -- Renal -- Hepatic -- Dosing Principles -- Dosing in Obese Patients -- REFERENCES -- 4 - The Role of Radiation Therapy in Hematopoietic Stem Cell Transplantation -- TOTAL-BODY IRRADIATION THERAPY -- Myeloablative Conditioning Regimens -- Reduced-Intensity Conditioning Regimens -- CNS Leukemic Involvement -- Toxicity after HSCT: contributions from TBI -- THE ROLE OF RT AMONG PATIENTS WITH HODGKIN LYMPHOMA AND NON-HODGKIN LYMPHOMA UNDERGOING HSCT -- Hodgkin Lymphoma -- Non-Hodgkin Lymphoma -- Toxicity Among HL and NHL Patients -- CONCLUSIONS -- DISCLOSURE STATEMENT -- REFERENCES -- III - WORKFLOWS AND PROCEDURES IN HEMATOPOIETIC CELL TRANSPLANTATION -- 5 - Sources of Cells for Hematopoietic Cell Transplantation: Practical Aspects of Hematopoietic Cell Collection -- INTRODUCTION -- SOURCES OF CELLS FOR ALLOGENEIC TRANSPLANTATION -- Bone Marrow -- Peripheral Blood -- Comparisons of Bone Marrow Versus Peripheral Blood -- Umbilical Cord Blood -- SOURCES OF CELLS FOR AUTOLOGOUS TRANSPLANTATION -- Growth Factor Mobilization -- Chemotherapy Plus GF Mobilization -- Growth Factor Plus CXCR4 Antagonist -- Comparison of Mobilization Strategies -- Mobilization Failures -- REFERENCES -- 6 - Patient and Donor Selection and Workup for Hematopoietic Cell Transplantation -- PATIENT SELECTION AND WORKUP -- Disease-Specific Factors -- Demographic Factors -- Comorbidities -- Patient-Reported Outcomes and Socio-Economic Factors. , Tools -- HLA Typing and the Search Procedure -- DONOR SELECTION AND WORKUP -- Donor Selection -- Donor type -- Donor Workup -- Donor suitability -- Risk to recipient -- Risk to the donor -- Donor assessment -- Conflict of interest -- Donor follow-up -- REFERENCES -- 7 - T-Cell Replete Haploidentical Transplantation -- INTRODUCTION -- POSTTRANSPLANTATION CYCLOPHOSPHAMIDE-BASED PLATFORM -- Haplo-SCT PT-Cy in Nonmalignant Diseases -- CONCLUSIONS -- REFERENCES -- 8 - Umbilical Cord Blood Transplantation -- INTRODUCTION -- History -- Cord Blood Collection, Processing, and Storage -- CORD BLOOD UNIT SELECTION -- Conditioning Regimens -- MAC regimens -- Reduced-intensity conditioning and non-myeloablative regimens -- Antithymocyte globulin -- Graft-versus-host disease -- Immune reconstitution -- FUTURE OF CORD BLOOD TRANSPLANTATION -- REFERENCES -- IV - HEMATOPOIETIC CELL TRANSPLANTATION FOR HEMATOLOGIC MALIGNANCIES -- 9 - Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia -- INTRODUCTION -- MECHANISMS OF ALLO-HSCT IN AML -- ACUTE MYELOID LEUKEMIA-DISEASE AND CLASSIFICATION -- RISK STRATIFICATION OF ACUTE MYELOID LEUKEMIA -- DYNAMIC RISK PROGNOSTICATION -- INDICATIONS FOR ALLO-HSCT -- CONDITIONING REGIMENS -- MYELOABLATIVE CONDITIONING -- REDUCED INTENSITY CONDITIONING -- NONMYELOABLATIVE CONDITIONING -- ALTERNATIVE DONOR TRANSPLANTATION -- TRANSPLANTATION IN INDUCTION FAILURE OR IN RELAPSE -- MANAGEMENT OF POSTTRANSPLANT RELAPSE -- PREVENTING AML RELAPSE WITH POST-HSCT MAINTENANCE THERAPY -- FUTURE DIRECTION -- REFERENCES -- 10 - Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia -- INTRODUCTION -- Allo-HCT in CR1 for Ph-Negative ALL -- Allo-HCT in CR1 for Ph-Positive ALL -- Question 1: Is Transplant Mandatory for all Ph-Positive ALL Patients? -- Question 2: Is Posttransplant TKI Maintenance Necessary?. , Question 3: Is There a Role for Autologous HCT for Ph-Positive Patients? -- ALLOGENEIC HSCT BEYOND CR1 -- OPTIMAL CONDITIONING AND DONOR SELECTION FOR ALLO-HCT FOR ALL -- Choice of Myeloablative Conditioning -- Choice of RIC -- Alternative Donors -- MUD Transplants -- UCB Transplants -- Haploidentical Transplants -- ADVANCES IN THE FIELD OF ALL -- Novel ALL Entities and Role of Allo-HCT for These Entities -- Early T precursor ALL -- Philadelphia-like ALL (BCR-ABL-like ALL) -- Incorporation of Novel Agents into the Treatment Algorithm of ALL -- Conclusion -- REFERENCES -- 11 - Hematopoietic Cell Transplantation for Myeloproliferative Neoplasms -- INTRODUCTION -- NONTRANSPLANT THERAPIES IN MF -- HCT IN MF -- HCT in Chronic Phase of MPN -- Risk Stratification of MF -- JAKi Therapy versus HCT -- Role of JAK Inhibitors in HCT -- Optimal Conditioning Therapy for HCT for MF -- What is the preferred graft source in MF? -- Splenectomy in the era of JAK inhibitors -- Alternative Donor Transplantation in Myelofibrosis -- Transplantation for MPN in AP/BP -- CONCLUSIONS -- DISCLOSURE STATEMENT -- REFERENCES -- 12 - Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia -- INTRODUCTION -- AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANT -- ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT -- Who Is Considered a Candidate for Allo-HCT in the Era of Novel Therapies? -- Richter Syndrome -- Does the Intensity of the Condition Regimen Matter? -- Novel Therapies in the Current Era -- Ibrutinib -- Idelalisib -- Venetoclax -- Chimeric Antigen Receptor-T Cells -- Other Experimental Agents -- DISCUSSION -- REFERENCES -- 13 - Allogeneic Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome -- INTRODUCTION -- WHO IS A CANDIDATE FOR ALLO-HCT? -- Patient-Related Factors -- Disease Characteristics -- Treatment-related MDS -- Hypoplastic MDS. , MDS originating from congenital mutations -- DONOR SELECTION -- SELECTING HEMATOPOIETIC CELL SOURCE -- THE ROLE OF PRETRANSPLANT DEBULKING TREATMENT -- SELECTION OF THE INTENSITY OF CONDITIONING REGIMENS -- POSTTRANSPLANTATION STRATEGIES -- Monitoring Residual Disease and Mixed Chimerism -- Prevention of Relapse after Allo-HCT -- Management of Posttransplant Relapse -- Management of Posttransplant Iron Overload -- REFERENCES -- 14 - Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin Lymphoma -- INTRODUCTION -- DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) -- FOLLICULAR LYMPHOMA -- MANTLE CELL LYMPHOMA -- MARGINAL ZONE LYMPHOMA -- SMALL LYMPHOCYTIC LYMPHOMA/CHRONIC LYMPHOCYTIC LEUKEMIA -- POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER -- PLASMABLASTIC LYMPHOMA -- CONCLUSION -- REFERENCES -- 15 - Allogenic Transplant for Non-Hodgkin Lymphoma -- INTRODUCTION -- B-CELL LYMPHOMAS -- ALLO-HCT FOR DLBCL -- Allo-HCT for DLBCL After Failed Auto-HCT -- Summary: DLBCL -- FOLLICULAR LYMPHOMA -- Overview of FL -- Allo-HCT for Relapsed, Refractory FL: Prospective Studies -- Allo-HCT for Relapsed, Refractory FL: Retrospective Studies -- Summary: FL -- MANTLE CELL LYMPHOMA -- Overview of MCL and Nontransplantation Options for Frontline Therapy -- Allo-HCT for Relapsed, Refractory MCL -- Summary: MCL -- ALLO-HCT IN OTHER RARE VARIANTS OF B-CELL NHL -- T-Cell Lymphomas -- Allogeneic Transplant in First Remission (Prospective Studies) -- RELAPSED/REFRACTORY T-CELL LYMPHOMA -- PTCL-NOS, ALCL, and AITL -- Allogeneic Transplant for Natural Killer/T-Cell Lymphoma -- Allogeneic Transplant for Hepatosplenic T-Cell Lymphoma -- Allogeneic Transplant for Adult T-Cell Leukemia/Lymphoma -- Allogeneic Transplant for Rare Mature T-Cell Neoplasms -- Allogeneic Transplant in Older Patients -- Future Directions in Allo-HCT for NHL -- REFERENCES. , 16 - Hematopoietic Stem Cell Transplantation for Hodgkin Lymphoma.
    Additional Edition: ISBN 0-323-56802-5
    Language: English
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Online Resource
    Charité
    KOBV
  • 2
    Online Resource
    Online Resource
    Hematopoietic cell transplantation for malignant conditions / (2019)
    St. Louis, Missouri :Elsevier,
    Details
    UID:
    (DE-602)edocfu_9960074094002883
    Format: 1 online resource (439 pages)
    ISBN: 0-323-56803-3
    Note: Front Cover -- Hematopoietic Cell Transplantation for Malignant Conditions -- Hematopoietic Cell Transplantation for Malignant Conditions -- Copyright -- List of Contributors -- Contents -- I - HISTORY AND BASIC SCIENCE OF HEMATOPOIETIC CELL TRANSPLANTATION -- 1 - History and Current Status of Hematopoietic Cell Transplantation -- INTRODUCTION -- BMT Developments in 1950s to Early 1960s -- The Significance of HLA Matching in Transplant -- Late 1960s: The First Successful HLA-Matched Sibling BMTs -- Late 1970s to Mid-1980s: Use of Unrelated Donors -- 1980−90: Use of PB as Autograft -- Early 1990s: Rapid Increase in Allogeneic Transplantation Using PB Grafts -- Haploidentical Stem Cell Transplantation -- History of Umbilical Cord Blood Transplant -- Late 1990s to Early 2000s: Introduction of RIC -- Origin of Donor and Transplant Registries -- CONCLUSION -- REFERENCES -- II - HEMATOPOIETIC CELL TRANSPLANTATION PHARMACOLOGY -- 2 - Pharmacology of Drugs Used in Hematopoietic Cell Transplantation -- INTRODUCTION -- IMMUNOSUPPRESSANTS -- Cyclosporine -- Pearls -- Tacrolimus -- Pearls -- Methotrexate -- Mycophenolate -- Sirolimus -- Pearls -- Cyclophosphamide -- Antithymocyte Globulin -- Pearls -- Alemtuzumab -- Pearls -- Corticosteroids -- Pearls -- ANTIMICROBIAL AGENTS -- Trimethoprim/Sulfamethoxazole -- Piperacillin/Tazobactam -- Pearl -- Cephalosporins -- Carbapenems -- Vancomycin -- Pearl -- Metronidazole -- Antivirals -- Antifungals -- ANTIDIARRHEAL AGENTS -- Loperamide -- Diphenoxylate and Atropine -- Octreotide -- MISCELLANEOUS -- Defibrotide -- Ursodiol -- Deferasirox -- Intravenous Immune Globulin -- Palifermin -- REFERENCES -- 3 - High-Dose Chemotherapy Regimens -- GOALS OF CONDITIONING REGIMENS -- TYPES OF CONDITIONING REGIMENS -- NONCHEMOTHERAPY AGENTS IN CONDITIONING REGIMENS -- Total-Body Irradiation -- Radioisotopes and Radioimmunotherapy. , 90Y-Ibritumomab Tiuxetan -- CHEMOTHERAPY AGENTS IN CONDITIONING REGIMENS -- ALKYLATING AGENTS -- Busulfan -- Cyclophosphamide -- Ifosfamide -- Melphalan -- Thiotepa -- Carmustine -- Bendamustine -- ANTIMETABOLITES -- Fludarabine -- Clofarabine -- Cytarabine -- Gemcitabine -- PLATINUM AGENTS -- Carboplatin -- PLANT ALKALOIDS -- Etoposide -- ANTI-T CELL ANTIBODIES -- MONOCLONAL ANTIBODIES -- Rituximab -- DOSING CONSIDERATIONS -- Organ Dysfunction -- Renal -- Hepatic -- Dosing Principles -- Dosing in Obese Patients -- REFERENCES -- 4 - The Role of Radiation Therapy in Hematopoietic Stem Cell Transplantation -- TOTAL-BODY IRRADIATION THERAPY -- Myeloablative Conditioning Regimens -- Reduced-Intensity Conditioning Regimens -- CNS Leukemic Involvement -- Toxicity after HSCT: contributions from TBI -- THE ROLE OF RT AMONG PATIENTS WITH HODGKIN LYMPHOMA AND NON-HODGKIN LYMPHOMA UNDERGOING HSCT -- Hodgkin Lymphoma -- Non-Hodgkin Lymphoma -- Toxicity Among HL and NHL Patients -- CONCLUSIONS -- DISCLOSURE STATEMENT -- REFERENCES -- III - WORKFLOWS AND PROCEDURES IN HEMATOPOIETIC CELL TRANSPLANTATION -- 5 - Sources of Cells for Hematopoietic Cell Transplantation: Practical Aspects of Hematopoietic Cell Collection -- INTRODUCTION -- SOURCES OF CELLS FOR ALLOGENEIC TRANSPLANTATION -- Bone Marrow -- Peripheral Blood -- Comparisons of Bone Marrow Versus Peripheral Blood -- Umbilical Cord Blood -- SOURCES OF CELLS FOR AUTOLOGOUS TRANSPLANTATION -- Growth Factor Mobilization -- Chemotherapy Plus GF Mobilization -- Growth Factor Plus CXCR4 Antagonist -- Comparison of Mobilization Strategies -- Mobilization Failures -- REFERENCES -- 6 - Patient and Donor Selection and Workup for Hematopoietic Cell Transplantation -- PATIENT SELECTION AND WORKUP -- Disease-Specific Factors -- Demographic Factors -- Comorbidities -- Patient-Reported Outcomes and Socio-Economic Factors. , Tools -- HLA Typing and the Search Procedure -- DONOR SELECTION AND WORKUP -- Donor Selection -- Donor type -- Donor Workup -- Donor suitability -- Risk to recipient -- Risk to the donor -- Donor assessment -- Conflict of interest -- Donor follow-up -- REFERENCES -- 7 - T-Cell Replete Haploidentical Transplantation -- INTRODUCTION -- POSTTRANSPLANTATION CYCLOPHOSPHAMIDE-BASED PLATFORM -- Haplo-SCT PT-Cy in Nonmalignant Diseases -- CONCLUSIONS -- REFERENCES -- 8 - Umbilical Cord Blood Transplantation -- INTRODUCTION -- History -- Cord Blood Collection, Processing, and Storage -- CORD BLOOD UNIT SELECTION -- Conditioning Regimens -- MAC regimens -- Reduced-intensity conditioning and non-myeloablative regimens -- Antithymocyte globulin -- Graft-versus-host disease -- Immune reconstitution -- FUTURE OF CORD BLOOD TRANSPLANTATION -- REFERENCES -- IV - HEMATOPOIETIC CELL TRANSPLANTATION FOR HEMATOLOGIC MALIGNANCIES -- 9 - Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia -- INTRODUCTION -- MECHANISMS OF ALLO-HSCT IN AML -- ACUTE MYELOID LEUKEMIA-DISEASE AND CLASSIFICATION -- RISK STRATIFICATION OF ACUTE MYELOID LEUKEMIA -- DYNAMIC RISK PROGNOSTICATION -- INDICATIONS FOR ALLO-HSCT -- CONDITIONING REGIMENS -- MYELOABLATIVE CONDITIONING -- REDUCED INTENSITY CONDITIONING -- NONMYELOABLATIVE CONDITIONING -- ALTERNATIVE DONOR TRANSPLANTATION -- TRANSPLANTATION IN INDUCTION FAILURE OR IN RELAPSE -- MANAGEMENT OF POSTTRANSPLANT RELAPSE -- PREVENTING AML RELAPSE WITH POST-HSCT MAINTENANCE THERAPY -- FUTURE DIRECTION -- REFERENCES -- 10 - Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia -- INTRODUCTION -- Allo-HCT in CR1 for Ph-Negative ALL -- Allo-HCT in CR1 for Ph-Positive ALL -- Question 1: Is Transplant Mandatory for all Ph-Positive ALL Patients? -- Question 2: Is Posttransplant TKI Maintenance Necessary?. , Question 3: Is There a Role for Autologous HCT for Ph-Positive Patients? -- ALLOGENEIC HSCT BEYOND CR1 -- OPTIMAL CONDITIONING AND DONOR SELECTION FOR ALLO-HCT FOR ALL -- Choice of Myeloablative Conditioning -- Choice of RIC -- Alternative Donors -- MUD Transplants -- UCB Transplants -- Haploidentical Transplants -- ADVANCES IN THE FIELD OF ALL -- Novel ALL Entities and Role of Allo-HCT for These Entities -- Early T precursor ALL -- Philadelphia-like ALL (BCR-ABL-like ALL) -- Incorporation of Novel Agents into the Treatment Algorithm of ALL -- Conclusion -- REFERENCES -- 11 - Hematopoietic Cell Transplantation for Myeloproliferative Neoplasms -- INTRODUCTION -- NONTRANSPLANT THERAPIES IN MF -- HCT IN MF -- HCT in Chronic Phase of MPN -- Risk Stratification of MF -- JAKi Therapy versus HCT -- Role of JAK Inhibitors in HCT -- Optimal Conditioning Therapy for HCT for MF -- What is the preferred graft source in MF? -- Splenectomy in the era of JAK inhibitors -- Alternative Donor Transplantation in Myelofibrosis -- Transplantation for MPN in AP/BP -- CONCLUSIONS -- DISCLOSURE STATEMENT -- REFERENCES -- 12 - Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia -- INTRODUCTION -- AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANT -- ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT -- Who Is Considered a Candidate for Allo-HCT in the Era of Novel Therapies? -- Richter Syndrome -- Does the Intensity of the Condition Regimen Matter? -- Novel Therapies in the Current Era -- Ibrutinib -- Idelalisib -- Venetoclax -- Chimeric Antigen Receptor-T Cells -- Other Experimental Agents -- DISCUSSION -- REFERENCES -- 13 - Allogeneic Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome -- INTRODUCTION -- WHO IS A CANDIDATE FOR ALLO-HCT? -- Patient-Related Factors -- Disease Characteristics -- Treatment-related MDS -- Hypoplastic MDS. , MDS originating from congenital mutations -- DONOR SELECTION -- SELECTING HEMATOPOIETIC CELL SOURCE -- THE ROLE OF PRETRANSPLANT DEBULKING TREATMENT -- SELECTION OF THE INTENSITY OF CONDITIONING REGIMENS -- POSTTRANSPLANTATION STRATEGIES -- Monitoring Residual Disease and Mixed Chimerism -- Prevention of Relapse after Allo-HCT -- Management of Posttransplant Relapse -- Management of Posttransplant Iron Overload -- REFERENCES -- 14 - Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin Lymphoma -- INTRODUCTION -- DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) -- FOLLICULAR LYMPHOMA -- MANTLE CELL LYMPHOMA -- MARGINAL ZONE LYMPHOMA -- SMALL LYMPHOCYTIC LYMPHOMA/CHRONIC LYMPHOCYTIC LEUKEMIA -- POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER -- PLASMABLASTIC LYMPHOMA -- CONCLUSION -- REFERENCES -- 15 - Allogenic Transplant for Non-Hodgkin Lymphoma -- INTRODUCTION -- B-CELL LYMPHOMAS -- ALLO-HCT FOR DLBCL -- Allo-HCT for DLBCL After Failed Auto-HCT -- Summary: DLBCL -- FOLLICULAR LYMPHOMA -- Overview of FL -- Allo-HCT for Relapsed, Refractory FL: Prospective Studies -- Allo-HCT for Relapsed, Refractory FL: Retrospective Studies -- Summary: FL -- MANTLE CELL LYMPHOMA -- Overview of MCL and Nontransplantation Options for Frontline Therapy -- Allo-HCT for Relapsed, Refractory MCL -- Summary: MCL -- ALLO-HCT IN OTHER RARE VARIANTS OF B-CELL NHL -- T-Cell Lymphomas -- Allogeneic Transplant in First Remission (Prospective Studies) -- RELAPSED/REFRACTORY T-CELL LYMPHOMA -- PTCL-NOS, ALCL, and AITL -- Allogeneic Transplant for Natural Killer/T-Cell Lymphoma -- Allogeneic Transplant for Hepatosplenic T-Cell Lymphoma -- Allogeneic Transplant for Adult T-Cell Leukemia/Lymphoma -- Allogeneic Transplant for Rare Mature T-Cell Neoplasms -- Allogeneic Transplant in Older Patients -- Future Directions in Allo-HCT for NHL -- REFERENCES. , 16 - Hematopoietic Stem Cell Transplantation for Hodgkin Lymphoma.
    Additional Edition: ISBN 0-323-56802-5
    Language: English
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Online Resource
    FU Berlin
    KOBV
  • 3
    Online Resource
    Online Resource
    Hematopoietic Cell Transplantation for Malignant Conditions. (2019)
    Philadelphia : Elsevier
    Details
    UID:
    (DE-627)1669733610
    Format: 1 online resource (439 pages)
    ISBN: 9780323568036
    Content: Front Cover -- Hematopoietic Cell Transplantation for Malignant Conditions -- Hematopoietic Cell Transplantation for Malignant Conditions -- Copyright -- List of Contributors -- Contents -- I - HISTORY AND BASIC SCIENCE OF HEMATOPOIETIC CELL TRANSPLANTATION -- 1 - History and Current Status of Hematopoietic Cell Transplantation -- INTRODUCTION -- BMT Developments in 1950s to Early 1960s -- The Significance of HLA Matching in Transplant -- Late 1960s: The First Successful HLA-Matched Sibling BMTs -- Late 1970s to Mid-1980s: Use of Unrelated Donors -- 1980−90: Use of PB as Autograft -- Early 1990s: Rapid Increase in Allogeneic Transplantation Using PB Grafts -- Haploidentical Stem Cell Transplantation -- History of Umbilical Cord Blood Transplant -- Late 1990s to Early 2000s: Introduction of RIC -- Origin of Donor and Transplant Registries -- CONCLUSION -- REFERENCES -- II - HEMATOPOIETIC CELL TRANSPLANTATION PHARMACOLOGY -- 2 - Pharmacology of Drugs Used in Hematopoietic Cell Transplantation -- INTRODUCTION -- IMMUNOSUPPRESSANTS -- Cyclosporine -- Pearls -- Tacrolimus -- Pearls -- Methotrexate -- Mycophenolate -- Sirolimus -- Pearls -- Cyclophosphamide -- Antithymocyte Globulin -- Pearls -- Alemtuzumab -- Pearls -- Corticosteroids -- Pearls -- ANTIMICROBIAL AGENTS -- Trimethoprim/Sulfamethoxazole -- Piperacillin/Tazobactam -- Pearl -- Cephalosporins -- Carbapenems -- Vancomycin -- Pearl -- Metronidazole -- Antivirals -- Antifungals -- ANTIDIARRHEAL AGENTS -- Loperamide -- Diphenoxylate and Atropine -- Octreotide -- MISCELLANEOUS -- Defibrotide -- Ursodiol -- Deferasirox -- Intravenous Immune Globulin -- Palifermin -- REFERENCES -- 3 - High-Dose Chemotherapy Regimens -- GOALS OF CONDITIONING REGIMENS -- TYPES OF CONDITIONING REGIMENS -- NONCHEMOTHERAPY AGENTS IN CONDITIONING REGIMENS -- Total-Body Irradiation -- Radioisotopes and Radioimmunotherapy.
    Note: Description based on publisher supplied metadata and other sources
    Additional Edition: 9780323568029
    Additional Edition: Erscheint auch als Druck-Ausgabe 9780323568029
    Language: English
    URL: lizenzpflichtig
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Online Resource
    GBV
  • 4
    Online Resource
    Online Resource
    Hematopoietic cell transplantation for malignant conditions / (2019)
    St. Louis, Missouri :Elsevier,
    Details
    UID:
    (DE-602)almahu_9948216258802882
    Format: 1 online resource (439 pages)
    ISBN: 0-323-56803-3
    Note: Front Cover -- Hematopoietic Cell Transplantation for Malignant Conditions -- Hematopoietic Cell Transplantation for Malignant Conditions -- Copyright -- List of Contributors -- Contents -- I - HISTORY AND BASIC SCIENCE OF HEMATOPOIETIC CELL TRANSPLANTATION -- 1 - History and Current Status of Hematopoietic Cell Transplantation -- INTRODUCTION -- BMT Developments in 1950s to Early 1960s -- The Significance of HLA Matching in Transplant -- Late 1960s: The First Successful HLA-Matched Sibling BMTs -- Late 1970s to Mid-1980s: Use of Unrelated Donors -- 1980−90: Use of PB as Autograft -- Early 1990s: Rapid Increase in Allogeneic Transplantation Using PB Grafts -- Haploidentical Stem Cell Transplantation -- History of Umbilical Cord Blood Transplant -- Late 1990s to Early 2000s: Introduction of RIC -- Origin of Donor and Transplant Registries -- CONCLUSION -- REFERENCES -- II - HEMATOPOIETIC CELL TRANSPLANTATION PHARMACOLOGY -- 2 - Pharmacology of Drugs Used in Hematopoietic Cell Transplantation -- INTRODUCTION -- IMMUNOSUPPRESSANTS -- Cyclosporine -- Pearls -- Tacrolimus -- Pearls -- Methotrexate -- Mycophenolate -- Sirolimus -- Pearls -- Cyclophosphamide -- Antithymocyte Globulin -- Pearls -- Alemtuzumab -- Pearls -- Corticosteroids -- Pearls -- ANTIMICROBIAL AGENTS -- Trimethoprim/Sulfamethoxazole -- Piperacillin/Tazobactam -- Pearl -- Cephalosporins -- Carbapenems -- Vancomycin -- Pearl -- Metronidazole -- Antivirals -- Antifungals -- ANTIDIARRHEAL AGENTS -- Loperamide -- Diphenoxylate and Atropine -- Octreotide -- MISCELLANEOUS -- Defibrotide -- Ursodiol -- Deferasirox -- Intravenous Immune Globulin -- Palifermin -- REFERENCES -- 3 - High-Dose Chemotherapy Regimens -- GOALS OF CONDITIONING REGIMENS -- TYPES OF CONDITIONING REGIMENS -- NONCHEMOTHERAPY AGENTS IN CONDITIONING REGIMENS -- Total-Body Irradiation -- Radioisotopes and Radioimmunotherapy. , 90Y-Ibritumomab Tiuxetan -- CHEMOTHERAPY AGENTS IN CONDITIONING REGIMENS -- ALKYLATING AGENTS -- Busulfan -- Cyclophosphamide -- Ifosfamide -- Melphalan -- Thiotepa -- Carmustine -- Bendamustine -- ANTIMETABOLITES -- Fludarabine -- Clofarabine -- Cytarabine -- Gemcitabine -- PLATINUM AGENTS -- Carboplatin -- PLANT ALKALOIDS -- Etoposide -- ANTI-T CELL ANTIBODIES -- MONOCLONAL ANTIBODIES -- Rituximab -- DOSING CONSIDERATIONS -- Organ Dysfunction -- Renal -- Hepatic -- Dosing Principles -- Dosing in Obese Patients -- REFERENCES -- 4 - The Role of Radiation Therapy in Hematopoietic Stem Cell Transplantation -- TOTAL-BODY IRRADIATION THERAPY -- Myeloablative Conditioning Regimens -- Reduced-Intensity Conditioning Regimens -- CNS Leukemic Involvement -- Toxicity after HSCT: contributions from TBI -- THE ROLE OF RT AMONG PATIENTS WITH HODGKIN LYMPHOMA AND NON-HODGKIN LYMPHOMA UNDERGOING HSCT -- Hodgkin Lymphoma -- Non-Hodgkin Lymphoma -- Toxicity Among HL and NHL Patients -- CONCLUSIONS -- DISCLOSURE STATEMENT -- REFERENCES -- III - WORKFLOWS AND PROCEDURES IN HEMATOPOIETIC CELL TRANSPLANTATION -- 5 - Sources of Cells for Hematopoietic Cell Transplantation: Practical Aspects of Hematopoietic Cell Collection -- INTRODUCTION -- SOURCES OF CELLS FOR ALLOGENEIC TRANSPLANTATION -- Bone Marrow -- Peripheral Blood -- Comparisons of Bone Marrow Versus Peripheral Blood -- Umbilical Cord Blood -- SOURCES OF CELLS FOR AUTOLOGOUS TRANSPLANTATION -- Growth Factor Mobilization -- Chemotherapy Plus GF Mobilization -- Growth Factor Plus CXCR4 Antagonist -- Comparison of Mobilization Strategies -- Mobilization Failures -- REFERENCES -- 6 - Patient and Donor Selection and Workup for Hematopoietic Cell Transplantation -- PATIENT SELECTION AND WORKUP -- Disease-Specific Factors -- Demographic Factors -- Comorbidities -- Patient-Reported Outcomes and Socio-Economic Factors. , Tools -- HLA Typing and the Search Procedure -- DONOR SELECTION AND WORKUP -- Donor Selection -- Donor type -- Donor Workup -- Donor suitability -- Risk to recipient -- Risk to the donor -- Donor assessment -- Conflict of interest -- Donor follow-up -- REFERENCES -- 7 - T-Cell Replete Haploidentical Transplantation -- INTRODUCTION -- POSTTRANSPLANTATION CYCLOPHOSPHAMIDE-BASED PLATFORM -- Haplo-SCT PT-Cy in Nonmalignant Diseases -- CONCLUSIONS -- REFERENCES -- 8 - Umbilical Cord Blood Transplantation -- INTRODUCTION -- History -- Cord Blood Collection, Processing, and Storage -- CORD BLOOD UNIT SELECTION -- Conditioning Regimens -- MAC regimens -- Reduced-intensity conditioning and non-myeloablative regimens -- Antithymocyte globulin -- Graft-versus-host disease -- Immune reconstitution -- FUTURE OF CORD BLOOD TRANSPLANTATION -- REFERENCES -- IV - HEMATOPOIETIC CELL TRANSPLANTATION FOR HEMATOLOGIC MALIGNANCIES -- 9 - Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia -- INTRODUCTION -- MECHANISMS OF ALLO-HSCT IN AML -- ACUTE MYELOID LEUKEMIA-DISEASE AND CLASSIFICATION -- RISK STRATIFICATION OF ACUTE MYELOID LEUKEMIA -- DYNAMIC RISK PROGNOSTICATION -- INDICATIONS FOR ALLO-HSCT -- CONDITIONING REGIMENS -- MYELOABLATIVE CONDITIONING -- REDUCED INTENSITY CONDITIONING -- NONMYELOABLATIVE CONDITIONING -- ALTERNATIVE DONOR TRANSPLANTATION -- TRANSPLANTATION IN INDUCTION FAILURE OR IN RELAPSE -- MANAGEMENT OF POSTTRANSPLANT RELAPSE -- PREVENTING AML RELAPSE WITH POST-HSCT MAINTENANCE THERAPY -- FUTURE DIRECTION -- REFERENCES -- 10 - Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia -- INTRODUCTION -- Allo-HCT in CR1 for Ph-Negative ALL -- Allo-HCT in CR1 for Ph-Positive ALL -- Question 1: Is Transplant Mandatory for all Ph-Positive ALL Patients? -- Question 2: Is Posttransplant TKI Maintenance Necessary?. , Question 3: Is There a Role for Autologous HCT for Ph-Positive Patients? -- ALLOGENEIC HSCT BEYOND CR1 -- OPTIMAL CONDITIONING AND DONOR SELECTION FOR ALLO-HCT FOR ALL -- Choice of Myeloablative Conditioning -- Choice of RIC -- Alternative Donors -- MUD Transplants -- UCB Transplants -- Haploidentical Transplants -- ADVANCES IN THE FIELD OF ALL -- Novel ALL Entities and Role of Allo-HCT for These Entities -- Early T precursor ALL -- Philadelphia-like ALL (BCR-ABL-like ALL) -- Incorporation of Novel Agents into the Treatment Algorithm of ALL -- Conclusion -- REFERENCES -- 11 - Hematopoietic Cell Transplantation for Myeloproliferative Neoplasms -- INTRODUCTION -- NONTRANSPLANT THERAPIES IN MF -- HCT IN MF -- HCT in Chronic Phase of MPN -- Risk Stratification of MF -- JAKi Therapy versus HCT -- Role of JAK Inhibitors in HCT -- Optimal Conditioning Therapy for HCT for MF -- What is the preferred graft source in MF? -- Splenectomy in the era of JAK inhibitors -- Alternative Donor Transplantation in Myelofibrosis -- Transplantation for MPN in AP/BP -- CONCLUSIONS -- DISCLOSURE STATEMENT -- REFERENCES -- 12 - Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia -- INTRODUCTION -- AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANT -- ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT -- Who Is Considered a Candidate for Allo-HCT in the Era of Novel Therapies? -- Richter Syndrome -- Does the Intensity of the Condition Regimen Matter? -- Novel Therapies in the Current Era -- Ibrutinib -- Idelalisib -- Venetoclax -- Chimeric Antigen Receptor-T Cells -- Other Experimental Agents -- DISCUSSION -- REFERENCES -- 13 - Allogeneic Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome -- INTRODUCTION -- WHO IS A CANDIDATE FOR ALLO-HCT? -- Patient-Related Factors -- Disease Characteristics -- Treatment-related MDS -- Hypoplastic MDS. , MDS originating from congenital mutations -- DONOR SELECTION -- SELECTING HEMATOPOIETIC CELL SOURCE -- THE ROLE OF PRETRANSPLANT DEBULKING TREATMENT -- SELECTION OF THE INTENSITY OF CONDITIONING REGIMENS -- POSTTRANSPLANTATION STRATEGIES -- Monitoring Residual Disease and Mixed Chimerism -- Prevention of Relapse after Allo-HCT -- Management of Posttransplant Relapse -- Management of Posttransplant Iron Overload -- REFERENCES -- 14 - Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin Lymphoma -- INTRODUCTION -- DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) -- FOLLICULAR LYMPHOMA -- MANTLE CELL LYMPHOMA -- MARGINAL ZONE LYMPHOMA -- SMALL LYMPHOCYTIC LYMPHOMA/CHRONIC LYMPHOCYTIC LEUKEMIA -- POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER -- PLASMABLASTIC LYMPHOMA -- CONCLUSION -- REFERENCES -- 15 - Allogenic Transplant for Non-Hodgkin Lymphoma -- INTRODUCTION -- B-CELL LYMPHOMAS -- ALLO-HCT FOR DLBCL -- Allo-HCT for DLBCL After Failed Auto-HCT -- Summary: DLBCL -- FOLLICULAR LYMPHOMA -- Overview of FL -- Allo-HCT for Relapsed, Refractory FL: Prospective Studies -- Allo-HCT for Relapsed, Refractory FL: Retrospective Studies -- Summary: FL -- MANTLE CELL LYMPHOMA -- Overview of MCL and Nontransplantation Options for Frontline Therapy -- Allo-HCT for Relapsed, Refractory MCL -- Summary: MCL -- ALLO-HCT IN OTHER RARE VARIANTS OF B-CELL NHL -- T-Cell Lymphomas -- Allogeneic Transplant in First Remission (Prospective Studies) -- RELAPSED/REFRACTORY T-CELL LYMPHOMA -- PTCL-NOS, ALCL, and AITL -- Allogeneic Transplant for Natural Killer/T-Cell Lymphoma -- Allogeneic Transplant for Hepatosplenic T-Cell Lymphoma -- Allogeneic Transplant for Adult T-Cell Leukemia/Lymphoma -- Allogeneic Transplant for Rare Mature T-Cell Neoplasms -- Allogeneic Transplant in Older Patients -- Future Directions in Allo-HCT for NHL -- REFERENCES. , 16 - Hematopoietic Stem Cell Transplantation for Hodgkin Lymphoma.
    Additional Edition: ISBN 0-323-56802-5
    Language: English
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Online Resource
    HU Berlin
    KOBV
  • 5
    Online Resource
    Online Resource
    Heomatopoietic cell transplantation for malignant conditions (2019)
    St. Louis, Missouri : Elsevier
    Details
    UID:
    (DE-627)1685483534
    Format: 1 Online-Ressource (1 online resource)
    ISBN: 0323568033 , 9780323568036
    Content: 90Y-Ibritumomab TiuxetanCHEMOTHERAPY AGENTS IN CONDITIONING REGIMENS; ALKYLATING AGENTS; Busulfan; Cyclophosphamide; Ifosfamide; Melphalan; Thiotepa; Carmustine; Bendamustine; ANTIMETABOLITES; Fludarabine; Clofarabine; Cytarabine; Gemcitabine; PLATINUM AGENTS; Carboplatin; PLANT ALKALOIDS; Etoposide; ANTI-T CELL ANTIBODIES; MONOCLONAL ANTIBODIES; Rituximab; DOSING CONSIDERATIONS; Organ Dysfunction; Renal; Hepatic; Dosing Principles; Dosing in Obese Patients; REFERENCES; 4 -- The Role of Radiation Therapy in Hematopoietic Stem Cell Transplantation; TOTAL-BODY IRRADIATION THERAPY
    Content: CorticosteroidsPearls; ANTIMICROBIAL AGENTS; Trimethoprim/Sulfamethoxazole; Piperacillin/Tazobactam; Pearl; Cephalosporins; Carbapenems; Vancomycin; Pearl; Metronidazole; Antivirals; Antifungals; ANTIDIARRHEAL AGENTS; Loperamide; Diphenoxylate and Atropine; Octreotide; MISCELLANEOUS; Defibrotide; Ursodiol; Deferasirox; Intravenous Immune Globulin; Palifermin; REFERENCES; 3 -- High-Dose Chemotherapy Regimens; GOALS OF CONDITIONING REGIMENS; TYPES OF CONDITIONING REGIMENS; NONCHEMOTHERAPY AGENTS IN CONDITIONING REGIMENS; Total-Body Irradiation; Radioisotopes and Radioimmunotherapy
    Content: Early 1990s: Rapid Increase in Allogeneic Transplantation Using PB GraftsHaploidentical Stem Cell Transplantation; History of Umbilical Cord Blood Transplant; Late 1990s to Early 2000s: Introduction of RIC; Origin of Donor and Transplant Registries; CONCLUSION; REFERENCES; II -- HEMATOPOIETIC CELL TRANSPLANTATION PHARMACOLOGY; 2 -- Pharmacology of Drugs Used in Hematopoietic Cell Transplantation; INTRODUCTION; IMMUNOSUPPRESSANTS; Cyclosporine; Pearls; Tacrolimus; Pearls; Methotrexate; Mycophenolate; Sirolimus; Pearls; Cyclophosphamide; Antithymocyte Globulin; Pearls; Alemtuzumab; Pearls
    Content: Front Cover; Hematopoietic Cell Transplantation for Malignant Conditions; Hematopoietic Cell Transplantation for Malignant Conditions; Copyright; List of Contributors; Contents; I -- HISTORY AND BASIC SCIENCE OF HEMATOPOIETIC CELL TRANSPLANTATION; 1 -- History and Current Status of Hematopoietic Cell Transplantation; INTRODUCTION; BMT Developments in 1950s to Early 1960s; The Significance of HLA Matching in Transplant; Late 1960s: The First Successful HLA-Matched Sibling BMTs; Late 1970s to Mid-1980s: Use of Unrelated Donors; 1980−90: Use of PB as Autograft
    Content: Get a quick, expert overview of hematologic and non-hematologic malignancies for which hematopoietic cell transplantation is a treatment option. Drs. Qaiser Bashir and Mehdi Hamadani provide easy-to-find information on basic science of hematopoietic cell transplantation, pharmacology, workflows and procedures, possible complications and side effects, in addition to the role of HCT in conjunction with clinical cellular therapy. Discusses high-dose chemotherapeutic regimens and radiation therapy, patient and donor selection and workup, as well as other key aspects of hematopoietic cell transplantation. Includes practical information on complications, infectious disease, and special populations such as patients with HIV infection. Consolidates today's available information in this fast-changing area into one convenient resource
    Content: Myeloablative Conditioning RegimensReduced-Intensity Conditioning Regimens; CNS Leukemic Involvement; Toxicity after HSCT: contributions from TBI; THE ROLE OF RT AMONG PATIENTS WITH HODGKIN LYMPHOMA AND NON-HODGKIN LYMPHOMA UNDERGOING HSCT; Hodgkin Lymphoma; Non-Hodgkin Lymphoma; Toxicity Among HL and NHL Patients; CONCLUSIONS; DISCLOSURE STATEMENT; REFERENCES; III -- WORKFLOWS AND PROCEDURES IN HEMATOPOIETIC CELL TRANSPLANTATION; 5 -- Sources of Cells for Hematopoietic Cell Transplantation: Practical Aspects of Hematopoietic Cell Collection; INTRODUCTION
    Note: SOURCES OF CELLS FOR ALLOGENEIC TRANSPLANTATION
    Additional Edition: 9780323568029
    Additional Edition: 9780323568036
    Additional Edition: 0323568025
    Additional Edition: 9780323568029
    Additional Edition: 0323568025
    Additional Edition: Erscheint auch als Druck-Ausgabe 9780323568036
    Additional Edition: Erscheint auch als Druck-Ausgabe 0323568025
    Additional Edition: 9780323568029
    Language: English
    Keywords: Electronic books
    URL: lizenzpflichtig
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Online Resource
    GBV
  • 6
    Book
    Book
    Hematopoietic cell transplantation for malignant conditions (2019)
    Amsterdam : St. Louis, Missouri
    Details
    UID:
    (DE-605)HT020027383
    Format: x, 428 Seiten , Illustrationen, Diagramme , 25 cm
    ISBN: 9780323568029
    Additional Edition: Erscheint auch als Online-Ausgabe 9780323568036
    Language: English
    URL: Inhaltsverzeichnis
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Book
    HBZ
  • 7
    Online Resource
    Online Resource
    Hematopoietic cell transplantation for malignant conditions (2019)
    Amsterdam : St. Louis, Missouri
    Details
    UID:
    (DE-605)HT021570931
    Format: 1 Online-Ressource (x, 428 Seiten) , Illustrationen, Diagramme
    ISBN: 9780323568036
    Additional Edition: Erscheint auch als Druck-Ausgabe Hematopoietic cell transplantation for malignant conditions 9780323568029
    Language: English
    DOI: 10.1016/C2017-0-01006-6
    URL: Volltext
    URL: Volltext
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Online Resource
    Online Access
    Open Access Request
    HBZ
  • 8
    Online Resource
    Online Resource
    A New Target for Hodgkin Lymphoma - Camidanlumab Tesirine (2021)
    Show associated volumes
    Details
    UID:
    (DE-101)1234906163
    Format: Online-Ressource , online resource.
    ISSN: 1558-822X , 1558-822X
    In: volume:16
    In: number:1
    In: day:25
    In: month:1
    In: year:2021
    In: pages:19-24
    In: date:2.2021
    In: Current hematologic malignancy reports, Philadelphia, Pa. : Current Science, 2006-, 16, Heft 1 (25.1.2021), 19-24, 2.2021, 1558-822X
    Language: English
    DOI: 10.1007/s11899-021-00604-w
    URN: urn:nbn:de:101:1-2021060621383905523184
    URL: https://doi.org/10.1007/s11899-021-00604-w
    URL: https://nbn-resolving.org/urn:nbn:de:101:1-2021060621383905523184
    URL: https://d-nb.info/1234906163/34
    URL: https://doi.org/10.1007/s11899-021-00604-w
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Online Resource
    Open Access Request
    DNB
  • 9
    Online Resource
    Online Resource
    Principal component-based hybrid model for time series forecasting (2023)
    Show associated volumes
    Details
    UID:
    (DE-101)130909361X
    Format: Online-Ressource, 1 online resource.
    ISSN: 2511-2112
    In: volume:15
    In: number:6
    In: day:23
    In: month:6
    In: year:2023
    In: pages:3045-3053
    In: date:8.2023
    In: International journal of information technology, [Singapore] : Springer Singapore, [march 2017]-, 15, Heft 6 (23.6.2023), 3045-3053, 8.2023, 2511-2112
    Language: English
    DOI: 10.1007/s41870-023-01343-2
    URN: urn:nbn:de:101:1-2023110810234097463975
    URL: https://doi.org/10.1007/s41870-023-01343-2
    URL: https://nbn-resolving.org/urn:nbn:de:101:1-2023110810234097463975
    URL: https://d-nb.info/130909361X/34
    URL: https://doi.org/10.1007/s41870-023-01343-2
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Online Resource
    Open Access Request
    DNB
  • 10
    Online Resource
    Online Resource
    Chimeric antigen receptor T cell therapy in multiple myeloma: promise and challenges (2020)
    Show associated volumes
    Details
    UID:
    (DE-101)1226839282
    Format: Online-Ressource , online resource.
    ISSN: 1476-5365 , 1476-5365
    In: volume:56
    In: number:1
    In: day:7
    In: month:8
    In: year:2020
    In: pages:9-19
    In: date:1.2021
    In: Bone marrow transplantation, London : Springer Nature, 1997-, 56, Heft 1 (7.8.2020), 9-19, 1.2021, 1476-5365
    Language: English
    DOI: 10.1038/s41409-020-01023-w
    URN: urn:nbn:de:101:1-2021020919300931625581
    URL: https://doi.org/10.1038/s41409-020-01023-w
    URL: https://nbn-resolving.org/urn:nbn:de:101:1-2021020919300931625581
    URL: https://d-nb.info/1226839282/34
    URL: https://doi.org/10.1038/s41409-020-01023-w
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Online Resource
    Open Access Request
    DNB
Nothing or not found what you are looking for? Please check your search query. For a search / Interlibrary loan from abroad use the search set "KOBV International" in the old KOBV portal.
Close ⊗
This website uses cookies and the analysis tool Matomo. Further information can be found on the KOBV privacy pages